4//SEC Filing
AFEYAN NOUBAR 4
Accession 0000950170-24-090211
CIK 0001682852other
Filed
Aug 1, 8:00 PM ET
Accepted
Aug 2, 7:00 PM ET
Size
14.2 KB
Accession
0000950170-24-090211
Insider Transaction Report
Form 4
Moderna, Inc.MRNA
AFEYAN NOUBAR
Director
Transactions
- Sale
Common Stock
2024-07-31$118.96/sh−4,599$547,107→ 2,234,416 total - Sale
Common Stock
2024-07-31$120.88/sh−3,428$414,377→ 2,225,324 total - Sale
Common Stock
2024-07-31$121.62/sh−1,309$159,204→ 2,224,015 total - Sale
Common Stock
2024-07-31$119.84/sh−5,664$678,754→ 2,228,752 total
Holdings
- 3,880,328(indirect: By Flagship Ventures Fund IV, L.P.)
Common Stock
- 747,897(indirect: By Flagship Ventures Fund IV-Rx, L.P.)
Common Stock
- 3,924(indirect: By Flagship Pioneering, Inc.)
Common Stock
Footnotes (8)
- [F1]These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.38 to $119.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.40 to $120.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.40 to $121.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.40 to $122.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F6]The shares are held directly by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
- [F7]The shares are held directly by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
- [F8]The shares are held directly by Flagship Pioneering, Inc. ("Flagship Pioneering"). The reporting person is the CEO and sole stockholder of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
Documents
Issuer
Moderna, Inc.
CIK 0001682852
Entity typeother
Related Parties
1- filerCIK 0001222012
Filing Metadata
- Form type
- 4
- Filed
- Aug 1, 8:00 PM ET
- Accepted
- Aug 2, 7:00 PM ET
- Size
- 14.2 KB